Refine by
Cancer Specific Antigen Articles & Analysis
11 articles found
Traditional cancer treatments do not possess the necessary precision to target only cancer cells which leads to poor treatment results and harmful side effects. ...
This specificity is achieved by linking a radioactive isotope to a monoclonal antibody or small molecule that targets specific cancer antigens. ...
They are generally proteins or polysaccharides found on the surface of pathogens, such as viruses, bacteria, or cancer cells. In the environment of cancer, antigens may be specific to tumor cells and are known as tumor-specific antigens (TSAs) or tumor-associated antigens (TAAs). ...
This analysis is mainly based on the following aspects:1. Ensure Specificity and TargetingThe main advantage of ADC lies in its high specificity for specific cancer cell surface antigens. Biological activity analysis can verify whether ADC can accurately identify and bind to target antigens. This ...
Antibodies are the precise guidance components of ADCs. In theory, molecules that bring effector molecules to the surface of tumor cells can play the role of antibody guidance The choice of antibody for ADC drugs depends on the target of the disease. Targets can be divided into tumor-specific antigens (TSA) and tumor-associated antigens (TAA) according to their expression. Antigens that are only ...
Role of mesothelin in cancer and signaling Mesothelin is expressed in many solid tumors, most commonly in mesothelioma, epithelial ovarian, and pancreatic cancers, as well as in lung and uterine malignancies and bile duct cancer. ...
Adoptive cell transfer (ACT) therapy is one of the most effective therapeutic options for tumor immunotherapy that is currently emerging in clusters. Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) are the main adoptive immunotherapies in recent years. TCR-engineered T cells express tumor antigen-specific receptors with alpha and beta chains generated from high-quality, ...
The researchers expose us to a radically different way of thinking in this article: instead of working on T cells, they focus on changing cancer cell antigens. They employed antibodies to deliver viral antigens to the tumor location and trigger virus-specific T lymphocytes to target cancer cells, destroying them. ...
In the study, the researchers propose a new method that mainly involves extensive screening of monoclonal antibodies against primary human tumor samples with the aim of identifying cancer-specific conformational epitopes throughout the protein that cannot be identified by transcriptome or proteome analysis. ...
Antibody-drug conjugate (ADC), a compound that connects a cytotoxic small-molecule drug to a monoclonal antibody via a rationally established linker, which selectively delivers an efficient cytotoxic agent into the tumor, has made significant progress in the previous decade. The first ADC drug approved by the US FDA was gemtuzumab ozogamicin (Mylotarg) in 2009. Currently, the FDA has authorized ...
Gene-modified cell therapies (GMCTs) represent the most effective therapeutic platform for many patients with advanced diseases including relapsed and refractory leukemia, non-Hodgkin lymphoma, and other blood cancers [1]. Specifically, chimeric antigen receptor T cell (CAR-T) therapies targeting CD19 have demonstrated remarkable responses and ...